SAFETY DATA SHEET

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture	RELVAR (ROW)/ BREO (US) ELLIPTA
Registration number	-
Synonyms	RELVAR ELLIPTA * BREO ELLIPTA * FLUTICASONE FUROATE/VILANTEROL ELLIPTA * FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER * FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER (50/25MCG) * FLUTICASONE FUROATE/VILANTEROL INHALATION POWDER (100/25MCG)
Issue date	15-May-2013
Version number	02
Revision date	15-May-2013

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses	Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.
Uses advised against	No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES (by country / geographic region):

Africa / EU / Israel / Middle East (English / European languages):	+44 (0) 1235 239 670
Asia Pacific (except China):	+65 3158 1074
China:	+86 10 5100 3039
Middle East / Africa (Arabic-speaking countries):	+44 (0) 1235 239 671
US:	+1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information None.

2.3. Other hazards Caution - Pharmaceutical agent.
This product is expected to be combustible, based on components present.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
FLUTICASONE FUROATE	0.4 - 3.2	397864-44-7 -	-	-	
Classification:	**DSD:**	Repr. Cat. 2;R61, Repr. Cat. 3;R62, Xn;R48/20/21			
	CLP:	Repr. 1B;H360, Repr. 1B;H360D, Repr. 2;H361, Repr. 2;H361f, STOT RE 2;H373			
MAGNESIUM STEARATE	1	557-04-0 209-150-3	-	-	
Classification:	**DSD:**	Xi;R36/37/38			
	CLP:	Skin Irrit. 2;H315, Eye Irrit. 2;H319, STOT SE 3;H335			
VILANTEROL	0.1 - 0.4	503070-58-4 -	-	-	
Classification:	**DSD:**	N;R51/53			
	CLP:	STOT RE 2;H373, Aquatic Chronic 2;H411			

Other components below reportable levels >95.0

CLP: Regulation No. 1272/2008.
DSD: Directive 67/548/EEC.
M: M-factor
vPvB: very persistent and very bioaccumulative substance.
PBT: persistent, bioaccumulative and toxic substance.
#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information If you feel unwell, seek medical advice (show the label where possible).

4.1. Description of first aid measures

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

Skin contact Rinse skin with water/shower. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. Get medical attention if symptoms occur.

4.2. Most important symptoms and effects, both acute and delayed The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; changes in clinical chemistry parameters; headache; inflamed nasal cavity; back pain; changes in blood pressure; altered heart rate and pulse; pain; coughing.

4.3. Indication of any immediate medical attention and special treatment needed Treat symptomatically.

SECTION 5: Firefighting measures

General fire hazards This material is expected to be combustible.

5.1. Extinguishing media

Suitable extinguishing media Water fog. Foam. Dry chemical powder.

Unsuitable extinguishing media Carbon dioxide (CO2).

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures In the event of fire, cool tanks with water spray.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. For personal protection, see section 8.

For emergency responders	Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the MSDS.
6.2. Environmental precautions	Avoid discharge into drains, water courses or onto the ground.
6.3. Methods and material for containment and cleaning up	Stop the flow of material, if this is without risk. Following product recovery, flush area with water.
6.4. Reference to other sections	For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling	Avoid prolonged exposure. Use care in handling/storage.
7.2. Conditions for safe storage, including any incompatibilities	Store in accordance with local/regional/national/international regulation. Store away from incompatible materials (see Section 10 of the MSDS).
7.3. Specific end use(s)	Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Type	Value	Note
FLUTICASONE FUROATE (CAS 397864-44-7)	8 HR TWA	6 mcg/m3	
	OHC	4	Reproductive hazard
		4	Skin
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1	
VILANTEROL (CAS 503070-58-4)	15 MIN STEL	20 mcg/m3	
	8 HR TWA	2 mcg/m3	
	ADE	5 µg/day	
	OHC	4	

Biological limit values	No biological exposure limits noted for the ingredient(s).
Recommended monitoring procedures	Follow standard monitoring procedures.
Derived No Effect Level (DNEL)	Not available.
Predicted no effect concentrations (PNECs)	Not available.

8.2. Exposure controls

Appropriate engineering controls	Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

Individual protection measures, such as personal protective equipment

General information	Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment.
Eye/face protection	If contact is likely, safety glasses with side shields are recommended. (eg. EN 166)
Skin protection	
- Hand protection	For prolonged or repeated skin contact use suitable protective gloves. The selection of gloves for a specific activity must be based on the material's properties and on possible permeation and degradation that may occur under the circumstances of use. Glove selection must take into account any solvents and other hazards present. Care must be exercised if insufficient data are available and further guidance should be sought from your local EHS department. Potential allergic reactions can occur with certain glove materials (e.g. Latex) and therefore these should be avoided. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).
- Other	Wear suitable protective clothing. (EN 14605 for splashes, EN ISO 13982 for dust)
Respiratory protection	When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387).
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

Environmental exposure controls

Hazard guidance and control recommendations Not available.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid.

Form Dry powder.Inhaler.

Colour Not available.

Odour Not available.

Odour threshold Not available.

pH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling range Not available.

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%) Not available.

Flammability limit - upper (%) Not available.

Vapour pressure Not available.

Vapour density Not available.

Relative density Not available.

Solubility(ies) Not available.

Partition coefficient (n-octanol/water) Not available.

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

Explosive properties Not available.

Oxidizing properties Not available.

9.2. Other information No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous reactions No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoid Contact with incompatible materials.

10.5. Incompatible materials None known.

10.6. Hazardous decomposition products Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Ingestion Health injuries are not known or expected under normal use.

Inhalation Health injuries are not known or expected under normal use.

Skin contact	Health injuries are not known or expected under normal use.
Eye contact	Health injuries are not known or expected under normal use.
Symptoms	The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; changes in clinical chemistry parameters; headache; inflamed nasal cavity; back pain; changes in blood pressure; altered heart rate and pulse; pain; coughing.

11.1. Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use.

Components	Species	Test results
FLUTICASONE FUROATE (CAS 397864-44-7)		
Acute		
Inhalation		
LCLo	Rat	> 0.133 mg/l
Oral		
LD50	Mouse	> 2000 mg/kg
	Rat	> 2000 mg/kg
Subacute		
Inhalation		
LOEL	Dog	<= 10.4 mg/kg/day, 4 weeks, Pharmacological effects
		<= 9 mg/kg/day, 4 weeks, Pharmacological effects
	Rat	<= 6.9 mg/kg/day, 4 weeks, Pharmacological effects
Subchronic		
Inhalation		
LOEL	Dog	<= 13 mcg/kg/day, 39 weeks, Pharmacological effects
		<= 11 mcg/kg/day, 13 weeks, Pharmacological effects
	Mouse	<= 7 mcg/kg/day, 13 weeks, Pharmacological effects
	Rat	<= 24 mcg/kg/day, 13 weeks, Pharmacological effects
		<= 20 mcg/kg/day, 26 weeks, Pharmacological effects
MAGNESIUM STEARATE (CAS 557-04-0)		
Acute		
Oral		
LD50	Rat	> 2000 mg/kg
VILANTEROL (CAS 503070-58-4)		
Acute		
Oral		
LD		> 300 mg/kg
Subchronic		
Inhalation		
NOAEL	Dog	62.5 mcg/kg/day, 39 weeks, heart, respiratory tract irritation
		9.3 mcg/kg/day, 13 weeks, heart, respiratory tract irritation
	Mouse	38200 mcg/kg/day, 13 weeks, clinical signs, mortality
	Rat	658 mcg/kg/day, 13 weeks, respiratory tract irritation
		58 mcg/kg/day, 26 weeks, respiratory tract irritation
NOEL	Dog	< 9.3 mcg/kg/day, 13 weeks, adrenergic effects

Components	Species	Test results
		< 9.55 mcg/kg/day, 39 weeks, adrenergic effects
	Mouse	< 59 mcg/kg/day, 13 weeks, adrenergic effects
	Rat	< 56 mcg/kg/day, 13 weeks, adrenergic effects
		< 58 mcg/kg/day, 26 weeks, adrenergic effects

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Corrosivity

FLUTICASONE FUROATE	OECD 404 Result: negative Species: Rabbit
VILANTEROL	Reconstituted Human Epidermis Result: negative

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE	0

Serious eye damage/eye irritation

Eye

FLUTICASONE FUROATE	0.05 % Acute Occular irritation Result: negative Species: Rabbit Read across, Read across, Fluticasone propionate Result: negative Species: Rabbit
VILANTEROL	Reconstituted Human Corneal Epithelium (HCE) Result: negative

Respiratory sensitisation Due to lack of data the classification is not possible.

Skin sensitisation

Sensitisation

VILANTEROL	50 % OECD 429, Vehicle - Dimethyl formamide Result: negative
FLUTICASONE FUROATE	Read across, Fluticasone propionate Result: negative Species: Guinea pig

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.

Germ cell mutagenicity

Germ cell mutagenicity: Ames test

VILANTEROL	ICH S 2 (R1) Result: negative

Germ cell mutagenicity: Micronucleus

VILANTEROL	ICH S 2 (R1) Result: negative

Mutagenicity

FLUTICASONE FUROATE	Ames Result: negative Chromosomal aberration assay Result: negative
VILANTEROL	L5178Y mouse lymphoma thymidine kinase locus assay, GW642444H Result: negative L5178Y mouse lymphoma thymidine kinase locus assay, GW642444H, DNA damage occurred only at cytotoxic concentrations. Result: positive
FLUTICASONE FUROATE	Mouse Lymphoma Cell (L5178Y) Assay Result: negative Rat Micronucleus Assay Result: negative
VILANTEROL	Rat UDS assay, GW642444H Result: negative

Mutagenicity

VILANTEROL	Syrian Hamster Embryo (SHE) cell transformation assay, GW642444H Result: negative bacterial mutation assay (high throughput fluctuation test), GW642444H Result: negative

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. Not classifiable as to carcinogenicity to humans.

VILANTEROL	> 10.5 mcg/kg/day ICH S1B - Inhalation, NOAEL Result: negative Species: Rat Test Duration: 104 weeks > 6.4 mcg/kg/day ICH S1B - Inhalation, NOAEL Result: negative Species: Mouse Test Duration: 104 weeks > 62 mcg/kg/day ICH S1B - Inhalation, Species-specific Result: positive Species: Mouse Organ: Uterus/ Ovary Test Duration: 104 weeks > 84.4 mcg/kg/day ICH S1B - Inhalation, Species-specific Result: positive Species: Rat Organ: Pituitary/ Ovary Test Duration: 104 weeks
FLUTICASONE FUROATE	ICH S1B - Inhalation Result: negative Species: Mouse ICH S1B - Inhalation Result: negative Species: Rat

Reproductive toxicity Components in this product have been shown to cause birth defects and reproductive disorders in laboratory animals.

Reproductive toxicity

Developmental effects

VILANTEROL	30 mcg/kg/day S5(R2) Sub-cutaneous, NOAEL Result: negative Species: Rabbit 300 mcg/kg/day S5(R2) Sub-cutaneous Result: positive Species: Rabbit Organ: Eye 300 mcg/kg/day S5(R2) Sub-cutaneous Result: positive Species: Rabbit Organ: Skeleton > 33700 mcg/kg/day S5(R2) Result: negative Species: Rat

Fertility effects - Females

VILANTEROL	> 10000 mcg/kg/day ICH S5(R2) Pre- and post-natal, oral Result: negative Species: Rat > 37112 mcg/kg/day ICH S5(R2), Inhalation Result: negative Species: Rat

Fertility effects - Males

VILANTEROL	> 33700 mcg/kg/day ICH S5(R2), Inhalation Result: negative Species: Rat

Reproductivity

FLUTICASONE FUROATE	8 mcg/kg/day Embryofetal Development Result: NOAEL Species: Rabbit 91 mcg/kg/day Female Fertility / Early Embryonic Development Result: reduced foetal bodyweight, minor skeletal variations Species: Rat

Reproductivity

FLUTICASONE FUROATE	>= 47 mcg/kg/day Embryofetal Development Result: Maternal weight loss/ Foetal abortion Species: Rabbit Male Fertility Result: No effect Species: Rat

Specific target organ toxicity - single exposure Heart.

Specific target organ toxicity - repeated exposure Immune system. Adrenal glands. Bone tissue.

Aspiration hazard Due to lack of data the classification is not possible.

Mixture versus substance information Not available.

Other information Caution - Pharmaceutical agent.

SECTION 12: Ecological information

12.1. Toxicity Contains a substance which causes risk of hazardous effects to the environment.

Components		Species	Test results
FLUTICASONE FUROATE (CAS 397864-44-7)			
Acute			
	NOEC	Activated sludge	1000, 3 hours, Nominal
Other	IC50	Activated sludge of a predominantly domestic sewage	> 1000 mg/l, 3 hours, Nominal
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	> 4.2 mg/l, 48 hours, Static renewal test
	NOEC	Water flea (Daphnia magna)	4.2 mg/l, 48 hours, Static renewal test
Terrestrial			
Acute			
Earthworm	EC50	Manure worm (Eisenia foetida)	> 1000 mg/kg, 14 days, Measured
	NOEC	Manure worm (Eisenia foetida)	1000 mg/kg, 14 days
MAGNESIUM STEARATE (CAS 557-04-0)			
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
Microtox	EC50	Microtox	12.5 mg/l, 15 minutes
VILANTEROL (CAS 503070-58-4)			
Aquatic			
Acute			
Algae	EC50	Green algae (Pseudokirchnereilla subcapitata)	1.33 mg/l, 72 hours, Nominal
	NOEC	Algae	0.139 mg/l, 72 hours
Chronic			
Crustacea	LOEC	Water flea (Daphnia magna)	18.25 mg/l, 21 days, semi-static test conditions
	NOEC	Daphnia	9.125 mg/l, 21 days
Fish	Growth test LOEC	Fathead minnow (Juvenile Pimephales promelas)	1.62 mg/l, 28 days, Nominal
	Growth test NOEC	Fish	0.54 mg/l, 28 days

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability No data is available on the degradability of this product.

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE	17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE	210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

FLUTICASONE FUROATE	0 %, 28 days Modified MITI (II) Test., Activated sludge
MAGNESIUM STEARATE	77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE	95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

FLUTICASONE FUROATE	2 - 3 %, 64 days, Soil
MAGNESIUM STEARATE	50 %, 13 days

12.3. Bioaccumulative potential No data available for this product.

Partition coefficient n-octanol/water (log Kow)

FLUTICASONE FUROATE	2.61 (Measured).
VILANTEROL	1.39

Bioconcentration factor (BCF)

MAGNESIUM STEARATE	> 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

FLUTICASONE FUROATE	3.6 - 4.2 Measured
MAGNESIUM STEARATE	5.86 Estimated

Mobility in general

Distribution

Octanol/water distribution coefficient log DOW

VILANTEROL	0.09 Measured., pH 5 1.35 Measured., pH 7 1.39 Measured., pH 9

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Always applicable.

Directive 94/33/EC on the protection of young people at work

Not regulated.

Other regulations	The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006. Pregnant women should not work with the product, if there is the least risk of exposure.
National regulations	Young people under 18 years old are not allow to work with this product according to the EU Directive 94/33/EC on the protection of young people at work.
15.2. Chemical safety assessment	No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations	Not available.
References	GSK Hazard Determination
Information on evaluation method leading to the classification of mixture	The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.
Full text of any statements or R-phrases and H-statements under Sections 2 to 15	R36/37/38 Irritating to eyes, respiratory system and skin. R48/20/21 Harmful: danger of serious damage to health by prolonged exposure through inhalation and in contact with skin. R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R61 May cause harm to the unborn child. R62 Possible risk of impaired fertility. H315 Causes skin irritation.

H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360 May damage the unborn child.
H360D May damage the unborn child.
H361 Suspected of damaging fertility.
H361f Suspected of damaging fertility.
H373 May cause damage to organs through prolonged or repeated exposure.
H411 Toxic to aquatic life with long lasting effects.

Revision information

Product and Company Identification: Synonyms
Composition / Information on Ingredients: Disclosure Overrides
SECTION 9: Physical and chemical properties: <INDENT>Form
Regulatory Information: United States

Training information

Follow training instructions when handling this material.

Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.